{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:17:20Z","timestamp":1785014240459,"version":"3.55.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.2217\/imt-2016-0074","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T10:07:56Z","timestamp":1482314876000},"page":"1437-1446","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Dermatologic Adverse Events of Checkpoint Inhibitors: What an Oncologist Should Know"],"prefix":"10.1080","volume":"8","author":[{"given":"Maya","family":"Habre","sequence":"first","affiliation":[{"name":"Department of Dermatology,St George Hospital University Medical Center,\rBeirut,\rLebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer Bassilios","family":"Habre","sequence":"additional","affiliation":[{"name":"Department of Plastic & Reconstructive Surgery,H\u00f4tel-Dieu de France,\rBeirut,\rLebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig R","family":"Kourie","sequence":"additional","affiliation":[{"name":"Oncology Department,Jules Bordet Institute,\rBrussels,\rBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"issue":"2","key":"e_1_3_2_8_1","article-title":"IMvigor 2, a Phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)","volume":"34","author":"Hoffman-Censits JH","year":"2016","unstructured":"Hoffman-Censits JH , GrivasP, Van Der HeijdenMSet al. IMvigor 2, a Phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J. Clin. Oncol.34(Suppl. 2S), Abstract 355 (2016).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0029"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.035"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8583","article-title":"Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma","volume":"29","author":"Ibrahim RA","year":"2011","unstructured":"Ibrahim RA , BermanDM, de PrilVet al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol.29(Suppl.), Abstract 8583 (2011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1024"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0455-8"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.963"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.166"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000017"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2297"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13058"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(83)70182-9"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000161122"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.028"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.2233"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-1-68"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260602"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"e_1_3_2_34_1","first-page":"1","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"16","author":"Totonchy MB","year":"2015","unstructured":"Totonchy MB , EzaldeinHH, KoCJ, ChoiJN. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol.16, 1\u20132 (2015).","journal-title":"JAMA Dermatol."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0249"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0134"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1643"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0582-1"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.2511"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.033"},{"key":"e_1_3_2_46_1","unstructured":"Yervoy (ipilimumab) US prescribing information: risk evaluation and mitigation strategy. Bristol-Myers Squibb Company Princeton NJ (2011). http:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.07.10"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2680"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2707"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2016-0074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:08:33Z","timestamp":1715951313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2016-0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.2217\/imt-2016-0074"],"URL":"https:\/\/doi.org\/10.2217\/imt-2016-0074","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}